The US Food and Drug Administration (USFDA) has made two observations on the manufacturing facility of Neuland Laboratories here.
The US regulator had inspected Neuland’s Unit 1 at Bonthapally, Hyderabad during April 3-7, 2017. ``At the end of the inspection, there were two observations given under form 483,” the Hyderabad-based company informed the Bombay Stock Exchange.
The two observations were related to procedures followed for the annual quality standards record evaluation and cleaning and maintenance of equipment at appropriate intervals during manufacturing campaign.
Neuland had already initiated corrective and preventive actions for the observations, it added.